ImmunityBio (IBRX) outlook covering core growth engines, ANKTIVA revenue, pipeline risks, bull vs bear case, and long-term investor value.
seen from Sweden
seen from Ukraine

seen from Malta
seen from Germany
seen from Finland
seen from South Korea
seen from United States
seen from United States
seen from United States
seen from China

seen from Bahrain
seen from China

seen from United States
seen from China
seen from Spain

seen from United States
seen from Malaysia
seen from Singapore
seen from China

seen from United States
ImmunityBio (IBRX) outlook covering core growth engines, ANKTIVA revenue, pipeline risks, bull vs bear case, and long-term investor value.
Jim Cramer, a well-known stock market analyst, has expressed caution towards investing in ImmunityBio, a biotech company specializing in immunotherapy treatments. During his “Lightning Round” segment on CNBC, Cramer stated that ImmunityBio is a “very risky” stock due to its high valuation and lack of tangible results. Cramer believes in the potential of immunotherapy but […]
Stock Market Analyst Jim Cramer Cautions Against Investing in ImmunityBio's Risky Immunotherapy Stock #biotechcompany #ImmunityBio #immunotherapy #JimCramer #stockmarketanalyst
Jim Cramer, a well-known stock market analyst, has expressed caution towards investing in ImmunityBio, a biotech company specializing in immunotherapy treatments. During his “Lightning Round” segment on CNBC, Cramer stated that ImmunityBio is a “very risky” stock due to its high valuation and lack of tangible results. Cramer believes in the potential of immunotherapy but […]
Stock Market Analyst Jim Cramer Cautions Against Investing in ImmunityBio's Risky Immunotherapy Stock #biotechcompany #ImmunityBio #immunotherapy #JimCramer #stockmarketanalyst
Oral COVID-19 vaccine being tested in California
- By Nuadox Crew -
A novel vaccine being developed could offer protection from COVID-19 without the need for an injection.